StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$39.10+0.17 (+0.44%)

Close on Nov 20, 2026Market cap $3.78BP/E –Yield –

CRISPR Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for CRISPR Therapeutics

CRISPR Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More CRISPR Therapeutics figures

See a number that looks wrong?